VSL#3 Resets Insulin Signaling and Protects against NASH and Atherosclerosis in a Model of Genetic Dyslipidemia and Intestinal Inflammation
Figure 4
Effect of VSL#3 on liver inflammation and fibrosis induced by DSS administration.
Histopathology analysis of liver, A) H&E staining and B) Sirus Red staining; original magnification 20×. C) Steatosis score; D) Inflammatory score and E) Fibrosis score. Data are mean ± SE of n = 8–12 mice per group. Liver content of inflammatory mediators including (F) TNFα, (G) RANTES, (H) ICAM-1, and (I) MIP-1α. Data are mean ± SE of n = 5 mice per group. * p<0.05 ApoE−/− experimental group versus naive wild type group; ** p<0.05 ApoE−/− naïve group versus ApoE−/− plus VSL#3 group; $ p<0.05 ApoE−/− naive group versus ApoE−/− plus DSS group; # p<0.05 ApoE−/− plus DSS group versus ApoE−/− plus DSS and VSL#3 group.